Cargando…
Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
Serological diagnostic of the severe respiratory distress syndrome coronavirus 2 (SARS-CoV-2) is a valuable tool for the determination of immunity and surveillance of exposure to the virus. In the context of an ongoing pandemic, it is essential to externally validate widely used tests to assure corr...
Autores principales: | Santano, Rebeca, Barrios, Diana, Crispi, Fàtima, Crovetto, Francesca, Vidal, Marta, Chi, Jordi, Izquierdo, Luis, Gratacós, Eduard, Moncunill, Gemma, Dobaño, Carlota |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460676/ https://www.ncbi.nlm.nih.gov/pubmed/34556736 http://dx.doi.org/10.1038/s41598-021-98296-y |
Ejemplares similares
-
Publisher Correction: Agreement between commercially available ELISA and in-house Luminex SARS-CoV-2 antibody immunoassays
por: Santano, Rebeca, et al.
Publicado: (2021) -
Performance of Multiplex Commercial Kits to Quantify Cytokine and Chemokine Responses in Culture Supernatants from Plasmodium falciparum Stimulations
por: Moncunill, Gemma, et al.
Publicado: (2013) -
Making sense of emerging evidence on the non-specific effects of the BCG vaccine on malaria risk and neonatal mortality
por: Bassat, Quique, et al.
Publicado: (2020) -
RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers
por: Aguilar, Ruth, et al.
Publicado: (2023) -
An Evaluation of Commercial Fluorescent Bead-Based Luminex Cytokine Assays
por: Djoba Siawaya, Joel Fleury, et al.
Publicado: (2008)